Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 7;101(40):e30273.
doi: 10.1097/MD.0000000000030273.

Brain metastasis from colorectal cancer: Treatment, survival, and prognosis

Wenxia Li  1 , Tongsheng Wang, Yubing Zhu, Haijiao Yu, Ling Ma, Yuhan Ding, Gao Hong, Ding Lei
Affiliations

Brain metastasis from colorectal cancer: Treatment, survival, and prognosis

Wenxia Li et al. Medicine (Baltimore). .

Abstract

To investigate the clinical characteristics, survival, prognostic factors, and treatment of brain metastasis (BM) from colorectal cancer (CRC). Twenty-one patients with BM from CRC were retrospectively reviewed. Predictive factors for BM and prognostic factors after the diagnosis of BM were examined by univariate and multivariate COX analysis. The time from the development of extracranial metastases, including lung, bone, and liver, to the occurrence of BM was recorded separately. The median overall survival time was 7 months. In univariate prognostic analysis, median survival with multimodal therapy was better than that with unimodal therapy (10 months vs 3 months, P = .000). In addition, median survival with Karnofsky performance status (KPS) < 70, 1 BM lesion, primary tumor stage of II-III, extracranial lesions < 2, and no extracranial metastasis were much better than the other groups (P < .05 of all). Although there was not a significant difference in median survival between patients receiving combination treatment with bevacizumab and those who did not, treatment with bevacizumab was associated with better survival (10 months vs 5 months, P = .436). The time intervals from bone, liver, and lung metastases to BM were 3, 6.5, and 11 months, respectively. Based on multivariate Cox analysis, KPS and treatment modalities were independent prognosis factors (P = .039 and P = .000, respectively). CRC patients with a high KPS and multimodal treatment have improved survival.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Kaplan–Meier survival analysis of patients with different KPS. KPS = Karnofsky performance status.
Figure 2.
Figure 2.
Kaplan–Meier survival analysis of patients with unimodal and multimodal treatment.
Figure 3.
Figure 3.
Magnetic resonance of BM with meningioma. BM = brain metastasis.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fedewa SA, et al. . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93. - PubMed
    1. Pan J, Xin L, Ma YF, et al. . Colonoscopy reduces colorectal cancer incidence and mortality in patients with non-malignant findings: a meta-analysis. Am J Gastroenterol. 2016;111:355–65. - PMC - PubMed
    1. Christensen TD, Spindler KL, Palshof JA, et al. . Systematic review: brain metastases from colorectal cancer – incidence and patient characteristics. BMC Cancer. 2016;16:260. - PMC - PubMed
    1. Cagney DN, Martin AM, Catalano PJ, et al. . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19:1511–21. - PMC - PubMed
    1. Nozawa H, Ishihara S, Kawai K, et al. . Brain metastasis from colorectal cancer: predictors and treatment outcomes. Oncology. 2017;93:309–14. - PubMed